[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360307-105":59,"doc-detail-360307-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mlh1-promoter-methylation-induced-dmmr-mss-in-endometrial-cancer-case-report","MLH1 promoter methylation-induced dMMR - MSS in endometrial cancer - case report","","Endometrial cancer (EC) is a common malignant tumor arising from the endometrial epithelium. Molecular classification supports treatment selection, prognosis assessment, and Lynch syndrome screening, where mismatch repair (MMR) deficiency and microsatellite instability (MSI) status guide immunotherapy. The case report describes poorly differentiated endometrioid carcinoma with MMR deficiency on testing but microsatellite stable (MSS) results, alongside genomic instability signals. MLH1 promoter methylation suggested partial suppression of MLH1 expression. For patients with dMMR by IHC but MSS by MSI testing, MLH1 promoter methylation testing is emphasized as critical for Lynch syndrome screening and more precise clinical decision-making.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mlh1-promoter-methylation-induced-dmmr-mss-in-endometrial-cancer-case-report/360307/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mlh1-promoter-methylation-induced-dmmr-mss-in-endometrial-cancer-case-report/360307.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does dMMR by IHC but MSS by MSI indicate in this case report?","Question",{"text":112,"@type":113},"The report presents a tumor showing MMR deficiency on testing while remaining microsatellite stable on MSI testing, indicating inconsistency between MMR and MSI status. Despite MSS, genomic instability signs were still observed.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was genomic instability assessed as part of the case findings?",{"text":117,"@type":113},"The case notes that, although the tumor was MSS, it exhibited signs of genomic instability. This supported the need to further evaluate underlying molecular mechanisms beyond MSI status alone.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is MLH1 promoter methylation testing considered critical here?",{"text":121,"@type":113},"The study suggests that MLH1 promoter methylation may partially suppress MLH1 expression. It concludes that when IHC shows dMMR but MSI testing shows MSS, MLH1 promoter methylation testing becomes more critical for Lynch syndrome screening and guiding treatment decisions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360307,1790193323,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Qu etal. Discover Oncology (2026) 17:819 [https://doi.org/10.1007/s12672-026-05050-9](https://doi.org/10.1007/s12672-026-05050-9)  \nDiscover Oncology  \nCASE REPORT Open Access  \nMLH1 promoter methylation-induced dMMR/  MSS in endometrial cancer: case report  \nZhen Qu1, Jinglin Mao1, Xiangyu Zhang1 and Longquan Xiang1*  \n*Correspondence:  \nLongquan Xiang [xianglongquan@126.com](xianglongquan@126.com)[ ](xianglongquan@126.com)1Department of Pathology, Jining No. 1 People’s Hospital, No. 269, Mengzi Avenue, High-tech Zone, Jining 272000, Shandong, China  \nAbstract  \nEndometrial cancer (EC) is a common malignant tumor in women, originating from the endometrial epithelium. Molecular classification of EC aids in guiding treatment, assessing prognosis, and screening for Lynch syndrome. Detection of mismatch repair (MMR) deficiency and microsatellite instability (MSI) status is crucial for guiding immunotherapy and Lynch syndrome screening. This study presentsa case of poorly differentiated endometrioid carcinoma, which exhibited MMR deficiency but was microsatellite stable (MSS) . Despite the MSS status, the tumor showed signs of genomic instability. Further MLH1 methylation testing suggested that MLH1 promoter methylation may have partially suppressed its expression. These results indicate that the immunohistochemistry (IHC) analysis yielded a negative result, whereas the MSI testing suggested that, although methylation of the MLH1 promoter allows MLH1 expression to largely maintain general genomic stability, it still exhibits signs of underlying instability. In conclusion, for endometrial cancer patients exhibiting dMMR by IHC but MSS by MSI testing, MLH1 promoter methylation testing becomes even more critical. This not only aids in screening for Lynch syndrome, enabling pathologists to make a more precise diagnosis, but also provides important guidance for clinical treatment decisions.  \nKeywords Endometrial cancer, MMR, MSI, MLH1 promoter methylation, Case report  \n1 Introduction  \nEndometrial cancer (EC), a common gynecological malignancy arising from the endometrial epithelium [1]. Factors such as increasing obesity rates, an aging population, and changing reproductive patterns contribute significantly to this trend [2, 3]. In 2023, endometrial cancer surpassed 400,000 new cases globally, becoming the most frequently diagnosed malignant tumor of the female reproductive system [4, 5]. Traditionally, primary treatment for early-stage disease involves surgery (hysterectomy and bilateral salpingo-oophorectomy, often with lymph node assessment), frequently combined with adjuvant radiation or chemotherapy based on established clinicopathological risk factors like stage, grade, depth of myometrial invasion, and lymphovascular space invasion [6].  \nWhile surgery and adjuvant therapies cure many patients with early-stage disease, outcomes for advanced or recurrent EC remain suboptimal, highlighting the need for more  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creati","cbCaikiB8k1JaEA2","https://ap.wps.com/l/cbCaikiB8k1JaEA2","pdf",2628546,11,"English","# Introduction\n## Molecular classification and clinical context\n## Rationale for MMR/MSI discordance and MLH1 methylation testing","[{\"question\":\"What does dMMR by IHC but MSS by MSI indicate in this case report?\",\"answer\":\"The report presents a tumor showing MMR deficiency on testing while remaining microsatellite stable on MSI testing, indicating inconsistency between MMR and MSI status. Despite MSS, genomic instability signs were still observed.\"},{\"question\":\"How was genomic instability assessed as part of the case findings?\",\"answer\":\"The case notes that, although the tumor was MSS, it exhibited signs of genomic instability. This supported the need to further evaluate underlying molecular mechanisms beyond MSI status alone.\"},{\"question\":\"Why is MLH1 promoter methylation testing considered critical here?\",\"answer\":\"The study suggests that MLH1 promoter methylation may partially suppress MLH1 expression. It concludes that when IHC shows dMMR but MSI testing shows MSS, MLH1 promoter methylation testing becomes more critical for Lynch syndrome screening and guiding treatment decisions.\"}]","MLH1 promoter methylation-induced dMMR - MSS in endometrial cancer - case report | PDF",1790139548,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1494cfb4efb919e5d8edb41110d1a470.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/72382e07419d2db2e737177e666a1f5c.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8ef01a86b95b9c067ba1aaa6b963cea1.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9fa729a14bd19a7019f60952216b9e9.webp",980,1306]